129 related articles for article (PubMed ID: 9269057)
1. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly.
Falsey AR; Walsh EE
Vaccine; 1997 Jul; 15(10):1130-2. PubMed ID: 9269057
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.
Piedra PA; Glezen WP; Kasel JA; Welliver RC; Jewel AM; Rayford Y; Hogerman DA; Hildreth SW; Paradiso PR
Vaccine; 1995 Aug; 13(12):1095-101. PubMed ID: 7491817
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.
Falsey AR; Walsh EE
Vaccine; 1996 Sep; 14(13):1214-8. PubMed ID: 8961507
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.
Gonzalez IM; Karron RA; Eichelberger M; Walsh EE; Delagarza VW; Bennett R; Chanock RM; Murphy BR; Clements-Mann ML; Falsey AR
Vaccine; 2000 Mar; 18(17):1763-72. PubMed ID: 10699324
[TBL] [Abstract][Full Text] [Related]
6. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis.
Piedra PA; Grace S; Jewell A; Spinelli S; Hogerman DA; Malinoski F; Hiatt PW
Pediatr Infect Dis J; 1998 Mar; 17(3):217-24. PubMed ID: 9535249
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.
Groothuis JR; King SJ; Hogerman DA; Paradiso PR; Simoes EA
J Infect Dis; 1998 Feb; 177(2):467-9. PubMed ID: 9466539
[TBL] [Abstract][Full Text] [Related]
8. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
11. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
Falloon J; Yu J; Esser MT; Villafana T; Yu L; Dubovsky F; Takas T; Levin MJ; Falsey AR
J Infect Dis; 2017 Dec; 216(11):1362-1370. PubMed ID: 29029260
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.
Paradiso PR; Hildreth SW; Hogerman DA; Speelman DJ; Lewin EB; Oren J; Smith DH
Pediatr Infect Dis J; 1994 Sep; 13(9):792-8. PubMed ID: 7808848
[TBL] [Abstract][Full Text] [Related]
13. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
14. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
[TBL] [Abstract][Full Text] [Related]
15. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
[TBL] [Abstract][Full Text] [Related]
16. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.
Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW
Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine.
Djagbare MD; Yu L; Parupudi A; Sun J; Coughlin ML; Rush BS; Sanyal G
Vaccine; 2018 Mar; 36(12):1673-1680. PubMed ID: 29456016
[TBL] [Abstract][Full Text] [Related]
18. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus.
Hancock GE; Smith JD; Heers KM
J Infect Dis; 2000 May; 181(5):1768-71. PubMed ID: 10823781
[TBL] [Abstract][Full Text] [Related]
19. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine.
Welliver RC; Tristram DA; Batt K; Sun M; Hogerman D; Hildreth S
J Infect Dis; 1994 Aug; 170(2):425-8. PubMed ID: 8035030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
